Physician profile
Walter Chan
NPI 1295875540
$11,430.52
in general payments reported to CMS, 2019-2025
13 companies · $565 in 2025
The $565 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2021: $2,073 · 2022: $2,249 · 2023: $5,467 · 2024: $607 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,096 · Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,096.00 |
| Food and Beverage | $1,543.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $5,166.27 | 2022-2023 | Dupixent |
| Genzyme Corporation | $2,226.85 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,006.25 | 2021 | |
| Medtronic, INC. | $638.09 | 2021-2025 | Endoflip, Gi Genius, Bravo |
| Merck Sharp & Dohme LLC | $360.00 | 2019 | |
| Intercept Pharmaceuticals, INC. | $285.73 | 2023-2024 | Ocaliva |
| Fujifilm Healthcare Americas Corporation | $136.42 | 2022 | |
| Boston Scientific Corporation | $123.79 | 2024 | |
| Intuitive Surgical, INC. | $111.88 | 2022 | |
| Covidien Lp | $108.18 | 2019 | |
| Gilead Sciences, INC. | $100.73 | 2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $98.99 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.34 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.